The ability of two plasmid DNA vaccines to stimulate lymphocytes from normal human donors and to generate antigen-specific responses is demonstrated. The first vaccine (truncated; tPSMA) encodes for only the extracellular domain of prostate-specific membrane antigen (PSMA). The product, expressed following transfection with this vector, is retained in the cytosol and degraded by the proteasomes. For the ''secreted'' (sPMSA) vaccine, a signal peptide sequence is added to the expression cassette and the expressed protein is glycosylated and directed to the secretory pathway. Monocyte-derived dendritic cells (DCs) are transiently transfected with either sPSMA or tPSMA plasmids. The DCs are then used to activate autologous lymphocytes in an in vitro model of DNA vaccination. Lymphocytes are boosted following priming with transfected DCs or with peptide-pulsed monocytes. Their reactivity is tested against tumor cells or peptide-pulsed T2 target cells. Both tPSMA DCs and sPSMA DCs generate antigen-specific cytotoxic T-cell responses. The immune response is restricted toward one of the four PSMA-derived epitopes when priming and boosting is performed with sPSMA. In contrast, tPSMA-transfected DCs prime T cells toward several PSMA-derived epitopes. Subsequent repeated boosting with transfected DCs, however, restricts the immune response to a single epitope due to immunodominance.
I mmunotherapy of prostate cancer could be a safe, noninvasive, relatively inexpensive procedure that can avoid bowel and bladder injury and impotence, which often result from surgical, cryosurgical or radiation therapy. Several groups have recently reported on the safety of DNA vaccines for immunizations against tumor antigens.
1-3 A possible target for prostate cancer immunotherapy is the prostate-specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II (GCPII). [4] [5] [6] [7] [8] PSMA expression is normally restricted to the prostate gland, brain tissue, jejunum and proximal kidney tubules. [9] [10] [11] Its expression is increased nearly 10-fold in prostate cancer cells and is also found in tumor but not normal neovasculature. 7, 12 The main effectors in antitumor immunity are CD8 + cytotoxic T cells that recognize tumor-associated antigen-derived peptides in association with major histocompatibility complex (MHC) class I molecules. [13] [14] [15] Gene-based vaccination in its current mode of application is effective in breaking tolerance to a self-antigen, but the response is narrow and is restricted to few of the potential epitopes. This presents a problem in vaccinology since loss of an MHC haplotype that participates in the conformation of the T-cell antigen, or point mutation in the recognized sequence would result in ineffective immune surveillance. [16] [17] [18] New vaccines and/or new methods of immunizations need to be developed for those instances. These hopefully will raise responses to subdominant determinants so that the selection of tumor escape variants that fail to express immunodominant epitopes will be prevented. 16 Numerous factors combine to establish an immunodominance hierarchy, 19 among which are the ineffective generation and transport of subdominant epitopes by antigen-presenting cells (APCs). Since proteasomal degradation is the main source of antigenic fragments destined for MHC presentation, 14 we speculated that purposeful cytosolic retention of newly synthesized tumor-associated antigens in genetically manipulated APCs would increase both the quantity and the diversity of such fragments. PSMA is a type II transmembrane glycoprotein which is comprised of 750 amino acids. 20, 21 It lacks a signal peptide sequence, and we speculated that elimination of sequences for its transmembrane region might impede the translocation of the encoded product to the endoplasmic reticulum. Such product should not be N-glycosylated, should be retained in the cytosol and rapidly degraded in the proteasome. In theory, dendritic cells (DC) transfected with such ''truncated'' sequences may have an advantage of presenting ''subdominant'' antigenic determinants that otherwise may not be generated at sufficient density to prime antigen-specific cytotoxic T-cell responses. The following experiments were designed to test this hypothesis in an in vitro immunization system with human cells.
Materials and methods
All human cellular material used in these experiments was obtained following informed consent through protocols approved by the local Committee for Bioethics (Bulgaria) or the Institutional Review Board (IRB) at George Washington University Medical Center in Washington, DC.
tPSMA and sPSMA plasmids construction
The cDNA encoding the extracellular portion (AA 44-750) of the human PSMA (XC-PSMA) was cloned into the pCR2.1 vector (Invitrogen, Carlsbad, CA) after RT-PCR of total mRNA from the human prostate cancer cell line LNCaP (CRL 1740, ATCC). The forward primer introduced a NotI cloning site and a Kozak sequence with a Met codon (GCCACCATG) into the 5 0 -end of XC-PSMA. The tPSMA plasmid for the transfection experiments was obtained by NotI-XhoI subcloning of XC-PSMA into a pVAX1 mammalian expression vector (Invitrogen, Carlsbad, CA). A secretable variant of the tPSMA plasmid -the sPSMA plasmid -was obtained by fusion of the XC-PSMA with a murine Ig k-chain leader sequence. The insert from tPSMA plasmid was subcloned by BamHI-XhoI into the mammalian expression vector pSecTag2A (Invitrogen, Carlsbad, CA), providing the murine Igk-chain leader sequence (clone 96). The single SfiI cloning site of the vector was used to fuse the XC-PSMA in-frame with the leader. The 5'-portion of the XC-PSMA between start Met and a single HpaI site was reamplified in order to introduce SfiI site (Met codon was not included). The SfiI-HpaI fragment of clone 96 was replaced with the PCR product predigested with the same restriction endonucleases, and the NruIXhoI fragment from obtained construct was moved to the pVAX1 vector. The inserts in both constructs are under the regulation of a human cytomegalovirus (CMV) immediate-early promoter/enhancer and a bovine growth hormone polyadenylation signal. The plasmid DNA specifications include: endotoxin content below 0.1 EU per microgram of DNA; lack of detectable amounts of bacterial RNA, genomic DNA or ssDNA as determined by agarose-gel electrophoresis; less than 10 mg of protein per 1 mg of plasmid DNA as determined by a colorimetric assay (Bio-Rad, Hercules, CA).
COS-1 transfection
Expression of PSMA constructs was performed in Cos-1 cells (ATCC). Monolayers were transfected with Fu-GENE 6 transfection reagent (Roche) and assayed for PSMA production by Western blot. Cos-1 cells were seeded in six-well tissue culture plates (Nunc, Denmark) at 1.5 Â 10 5 cells per well and grown to 50-70% confluence in DMEM supplemented with 25 mM HEPES (pH 7.5), 1 mM sodium pyruvate, 3.7 g/l sodium bicarbonate, 100 mg/ml penicillin, 100 mg/ml streptomycin, 0.25 mg/ml amphotericin B and 10% (v/v) of heatinactivated fetal bovine serum. Cos-1 cells were transfected with 1.5 mg of plasmid DNA precondensed with 4.5 ml of FuGENE 6 reagent in serum-free DMEM for 30 minutes at room temperature. Cells were then grown for 72 hours in supplemented DMEM and then harvested.
In the proteasome inhibition studies, lactacystin (Sigma) was added to the culture media (final concentration 10 mM) 24 hours before harvesting.
Cells were harvested by gentle scraping after double wash with 2 ml of cold PBS and by adding 0.25 ml of cold lysis buffer (0.5 M NaCl, 1% Triton X-100, 0.2% Tween 20, 50 mM HEPES, pH 7.0) to each well. Lysates were transferred to Eppendorf tubes and homogenized by repeated pipetting on ice.
For detection of secreted PSMA, the serum containing DMEM was removed 48 hours after transfection, the cells were washed twice with 2 ml of PBS, then serum-free DMEM (2 ml per well) was added and the cells were incubated for additional 24 hours in the six-well plates. After collection of the medium, the cell debris was removed by centrifugation (35,000 g, 20 minutes) and supernatants were concentrated with Centricon-50 centrifuge filtering device (Millipore) and stored at À301C until further use.
Deglycosylation of PSMA
The deglycosylation of PSMA proteins was carried out by treatment of 25 mg protein samples with 5 U of glycopeptidase F from Chryseobacterium Meningosepticum (Sigma) in 50 mM phosphate buffer (pH 7.5) containing 0.1% (w/v) SDS, 50 mM b-mercaptoethanol, 0.75% (v/v) Triton X-100 for 4 hours at 371C. 22 An extracellular portion of the human glutamate carboxypeptidase II (AA 44-750) in Drosophila Schneider's cells, purified to homogeneity, 23 was provided by Dr Jan Konvalinka, Institute of Organic Chemistry and Biochemistry, Czech Academy of Science, Prague, The Czech Republic.
Electrophoresis and immunoblotting
Immunoblotting and electrophoretic assays of cell lysates and culture supernatants were performed using NuPage BioTris electrophoretic system (Invitrogen). Protein samples in loading buffer were heated at 701C for 10 minutes and loaded on 10% Bis-Tris gels. After electrophoresis and electrotransfer, the nitrocellulose membrane was blocked with 1% casein in TBS/T for 40 minutes. The membranes were probed with poly-or monoclonal anti-PSMA Abs (see below) for 1 hour at RT. Detection was performed using goat anti-rabbit or anti-mouse IgG-HRP conjugates (Sigma) and visualized with WestPico Super Signal Chemo Luminescent Substrate (Pierce) in accordance with the manufacturer's recommendations.
Anti-human PSMA monoclonal antibodies Y-PSMA1 and Y-PSMA2 were obtained from Yes Biotech Laboratories Ltd (Mississauga, Ontario, Canada).
Cell culture and generation of monocytes-derived DCs
Cell cultures from peripheral blood mononuclear cells were maintained in research-grade serum-free AIM-V medium (Invitrogen, Carlsbad, CA). The human prostate cancer cell line LNCaP was purchased from ATCC and was maintained in RPMI supplemented with 10% FCS (Life Technologies Inc., Rockville, MD), 2 mM l-glutamine, 50 U/ml penicillin and 50 mg/ml streptomycin. The human T2 cell line is transporter associated with antigen processing (TAP) deficient, resulting in inefficient loading of leukocyte antigen class I molecules with endogenous peptides. 24 As a consequence, the HLA-A0201 molecules of T2 cells can be efficiently loaded with exogenous peptides. The T2 cell line was purchased from ATCC and maintained in IMDM supplemented with 20% FBS (Life Technologies Inc., Rockville, MD).
For T-cell stimulation, the leukocyte fraction was collected by leukapheresis and mononuclear cells were separated on a density gradient. Cells were resuspended in serum-free AIM-V medium at 2 Â 10 7 /ml and incubated for 2 hours in a humidified incubator at 371C. The nonadherent T-cell-enriched fraction and part of the adherent cells were harvested and frozen for future use. For convenience, these cells are referred to as ''T cells'' throughout the text despite the fact that this nonadherent fraction contains B cells and NK cells also.
The rest of the adherent cells were differentiated into DCs by culture in serum-free AIM-V medium supplemented with IL-4 (PeproTech, Rocky Hill, NJ) and GM-CSF (Oncology Supplies Inc., Dothan, AL) for 6 days. The nonadherent cells were harvested and used for transfection. Transfection was performed using the Nucleofectort device and the corresponding transfection kit (Amaxa GmbH, Cologne, Germany). The efficiency of Nucleofectort transfection of human DCs was 3278.8% (n ¼ 5), as estimated by control transfection with green fluorescence protein (GFP). Following transfection, DCs were resuspended in serum-free AIM-V medium and matured with TNF-a (Becton Dickinson Inc., Bedford, MA) at 371C for 24 hours. Following maturation, the DCs were resuspended in AIM-V medium at 1 Â 10 5 cells/ml.
In vitro genertion of CTL responses
For T-cell stimulation, the T-cell-enriched fraction was thawed, washed, resuspended in AIM-V medium and added to the DC suspension, so that the final concentration of the T-cell-enriched fraction was 1 Â 10 6 cells/ml. The cell suspension was then distributed into 24-well plates (1 ml/well) and cultured at 371C. After 3 days, the medium was replaced with serum-free AIV-M medium supplemented with human IL-2 (20 U/ml) and human IL-7 (10 U/ml) (PeproTech, Rocky Hill, NJ). The cells were additionally stimulated with autologous PSMA-transfected DCs (stimulator:effector ratio of 1:10) or with peptide-pulsed autologous monocytes (stimulator:effector ratio of 1:1) twice, 8 days apart.
For pulsing with peptides, monocytes were resuspended at 10 6 /ml in serum-free RPMI-1640 medium supplemented with l-glutamine and penicillin/streptomycin. Peptide was added to a final concentration of 0.05 mg/ml and the cells were incubated for 4 hours at 371C in a controlled CO 2 humidified incubator. The cells were then washed twice with serum-free medium, irradiated (1500 rad) and resuspended in IL-2-and IL-7-containing medium.
For cytotoxicity assays, target T2 cells were pulsed for 6 hours with 0.05 mg/ml peptide and 1 mCi/well After 20 days of culture, effector T cells were harvested without further separation for microcytotoxicity assays. The cells were analyzed by flow cytometry and 83710% of them were CD3 + and B45 or B60% of them were CD3 + CD8
+ when primed with sPSMA DCs, or tPSMA DCs respectively (data not shown).
For CTLA-4 inhibition experiments, Fab-fragments, prepared (see below) from anti-CD152 (HB-12319, ATCC) monoclonal antibody, were added (0.02 mg/ml final concentration) to the T cells at the initiation of culture or 6, 10 or 18 hours after that. The cultures were incubated for three additional days and the cells were washed and resuspended in IL-2-and IL-7-containing AIV-M medium.
Fab-fragment preparation of anti-CD152 monoclonal antibodies
Purified IgG (2 mg/ml in PBS) was cleaved with papain (Sigma) at a ratio 1:25 (w/w) of papain to IgG in the presence of 0.01 mM l-cystein at 371C for 5.5 hours. The reaction was stopped by the addition of N-ethylmaleimide to a final concentration of 30 mM. The Fab fragment was isolated by gel filtration with a Superdex 75 column (Pharmacia) followed by ion exchange column (ResourceQ, Pharmacia) chromatography. The buffer for the eluted protein was changed to 10 mM Tris-HCl (pH 7.4) by gel filtration, and the pooled protein was concentrated to 15 mg/ml with centricon-10 (Millipore). The protein was tested for purity at each step by SDS-PAGE under reduced and nonreduced conditions.
Cytotoxicity testing
Cytotoxicity against LNCaP cells or against peptidepulsed T2 cells (both HLA-A2-positive) was tested after Human dendritic cells genetically engineered M Mincheff et al 20 days of culture and compared to a control cell line that did not express PSMA. Cytotoxicity was tested using the JAM test. 25 Briefly, target or control cells were grown overnight with 3 H-thymidine, then washed, resuspended in complete RPMI-1640 medium and used in 4-hour cytotoxicity test. The killing was detected as a fall in counts per minute in cell samples undergoing apoptosis due to DNA fragmentation. All of the E:T ratios were tested in triplicate. Spontaneous cytotoxicity was determined in medium alone without effector cells.
Unlabeled K562 cells (no MHC expression, sensitive to natural killer cell-mediated lysis) were included at 50 Â the target cell number to inhibit nonspecific lysis. Control experiments involved the Malme M3 melanoma cell line, which is also HLA-A2 positive.
Cell lines
The human LNCaP (CRL-1740), T2 (CRL-1992), K562 and Malme 3M (HTB-64) cell lines were purchased from ATCC and were maintained according to ATCC instructions.
Flow cytometry analysis and antibodies used
Antibodies used to phenotype the cells were anti-CD1a, 
Statistics and epitope binding predictions
Analysis of cytotoxicity data was performed using twotailed Student's t-tests assuming equal variance. We used the predictive algorithm from the Bioinformatics and Molecular Analysis Section of the NIH (''BIMAS'') which was developed by Parker et al, 26 ranking potential MHC binders according to the predictive one-half-time disassociation of peptide/MHC complexes.
Peptide synthesis and purification
Peptides were custom synthesized and purified by Sigma Genosys (The Woodlands, TX).
Results

Selection of HLA-A2-binding PSMA peptides
The amino-acid sequence of the extracellular domain of PSMA was analyzed for the existence of 9-amino-acid peptides predicted to bind to HLA-A0201, the most common human MHC class I allele. Using the computerbased algorithm (http://bimas.cit.nih.gov/), four 9-mer peptides that contain binding motifs for the HLA-A0201 class I molecule were identified (Table 1) .
COS-1 cells transfected with tPSMA or sPSMA plasmids express the encoded product Following transfection with sPSMA plasmid, the encoded product is N-glycosylated (Fig 1) and could be detected intra-and extracellularly (i.e. is secreted) (data not shown). The product expressed following transfection with the tPSMA plasmid is not glycosylated, but is retained in the cytosol and rapidly degraded in the proteasome. It could be detected following proteasomal inhibition with lactacystin (Fig 2) . Score corresponds to the estimated half-time of dissociation of complexes containing the peptide at 371C at pH 6.5.
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Generation of mature DCs from peripheral blood monocytes
Immature DCs were generated from PBMC after 6 days of culture in GM-CSF-and IL-4-conditioned medium. DC appeared as nonadherent cells with the typical DC morphology and high expression of CD1a (80-90%). Treatment of tPSMA-and sPSMA-transfected DCs with TNF-a triggers a coordinate series of phenotypic changes, resulting in an upregulation of costimulatory molecules (CD80, CD86, CD40) and HLA class II antigens (Fig 3) .
Both tPSMA DCs and sPSMA DCs prime and support development of T cells that are cytotoxic against LNCaP cells
The T-cell-enriched fraction from each leukapheresis was primed and then boosted twice, at 8-day intervals with autologous PSMA-transfected DCs. Their cytotoxicity was then tested against LNCaP cells or control Malme M3 melanoma cells. Both tPSMA DCs and sPSMA DCs primed and supported development of T cells that are cytotoxic against LNCaP cells (Fig 4) .
tPSMA DCs, but not sPSMA DCs, prime T cells that are reactive to subdominant PSMA epitopes
Since proteasomal degradation is the main source of antigenic fragments destined for MHC class I presentation, 14 and since purposeful cytosolic retention of nonglycosylated and misfolded newly synthesized tumorassociated antigens enhances such degradation (Fig 2) , we reasoned that tPSMA-transfected DCs will have a greater potential to prime T cells specific for subdominant PSMA epitopes. To check this hypothesis, we primed the T-cellenriched fraction from each leukapheresis with mature tPSMA DCs or sPSMA DCs and boosted them twice, at 8-day intervals, with autologous monocytes pulsed with one of several PSMA-derived peptides (Table 1) . At 20 days after priming, cytotoxicity was tested against T2 cells pulsed with the same peptide used for boosting. Unlike the DCs transfected with the sPSMA plasmid, the tPSMA DCs prime T cells to all four PSMA-derived peptides in four of the five donors (Fig 5) .
CTLA-4 inhibition during sPSMA DC priming leads to stimulation of T cells reactive to subdominant epitopes
Lack of responses to the subdominant PSMA epitopes when DCs are transfected with sPSMA may result from complete lack of such epitopes on the membrane of the Figure 5 Induction of CTL responses with autologous DCs that have been transfected with the extracellular domain of PSMA. PBMCs that had been depleted of monocytes were primed with autologous DCs transfected with either sPSMA (triangles), tPSMA (squares) or control (mock, empty) plasmids (diamonds). Responding cultures were then boosted with monocytes pulsed with one of four HLA-A2-restricted PSMA-derived peptides (Table 1 ) and their cytotoxicity was tested against T2 cells pulsed with the same peptide that was used during boosting, or with a control 
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APCs. Alternatively, the epitopes may be generated, but factors other than T-cell receptor (TCR) signaling, such as the CTLA-4/B7 pathway, could be contributing to the ineffective proliferation of T cell to subdominant epitopes. Currently, there is a general consensus that effective activation of naive T cells requires two signals: one dependent on the engagement of the TCR by peptide-MHC complexes, and the second costimulatory signal that is provided by interactions between cell surface molecules on the T cell and the APC. 27 Numerous studies have indicated that the CD28 molecule, expressed on T cells, provides a potent costimulatory signal following engagement with its ligands, B7-1 and B7-2. 28 The costimulatory function of CD28 is counterbalanced by the existence of a second higher-affinity receptor for B7, termed CTLA-4. 29 The latter inhibits T-cell activation at instances of weak T-cell receptor engagement, 30 and we speculated that we could enhance T-cell stimulation to existing subdominant epitopes if we inhibited CTLA-4 signaling with anti-CTLA-4 Fab fragments. Indeed, CTLA-4 inhibition during sPSMA DC priming led to stimulation of T cells reactive to subdominant epitopes. We interpret this as evidence that subdominant epitopes are generated in DC transfected with the sPSMA plasmid but the response can be detected only after CTLA-4 inhibition (Fig 6) .
Since CTLA-4 was not expressed in resting T cells, we determined the time points during the 72-hour priming phase that the inhibitory control by CTLA-4 became apparent. The anti-CD152 antibody Fab fragments (20 mg/ml) were added either at the beginning, or at 6, 10 or 18 hours after the start of the culture. CTLA-4 inhibition was effective when performed early (0 or 6 hours) after initiation of culture (Fig 7) .
Repeated boosting with transfected DCs restricts the response toward one immunodominant epitope
Maturation of potent CTL effectors requires repetitive boosting with target antigen. To determine the effect of a prime/boost vaccination strategy on the clonality of the T-cell response, tPSMA DC-primed cultures, known to contain CTLs to subdominant epitopes (Fig 5) , were boosted with transfected or peptide-pulsed DCs or monocytes, and their cytotoxicity was tested against PSMA-peptide-pulsed T2 target cells. Boosting with either APCs that express multiple PSMA-derived epitopes (transfected DCs or DCs or monocytes pulsed with multiple peptides) restricts the immune response toward one immunodominant epitope (Table 2) . A subdominant T-cell response could only be preserved if boosting is performed with an APC pulsed with the particular subdominant epitope. Figure 6 CTLA-4 inhibition during sPSMA DC priming enhances stimulation to subdominant epitopes. HLA A2(+) PBMCs that had been depleted of monocytes were primed with autologous DCs transfected with either sPSMA plasmid (triangles) or control empty plasmid (diamonds) in the presence (open symbols) or absence (closed symbols) of blocking anti-CD152 Fab fragments. The Fab fragments were added at the initiation of the culture (final concentration 0.02 mg/ml). After 3 days, and then two more times at weekly intervals, the responding cultures were boosted with monocytes pulsed with one of two HLA-A2-restricted, PSMA-derived peptides (PSMA 707 or PSMA 668 ). Cytotoxicity was tested against T2 cells pulsed with the same peptide that was used during boosting, or with a control (influenza) peptide. Data points for the control peptide are not shown but are identical to those obtained in the control experiments with T cells primed with empty plasmid-transfected DCs. Each point represents the mean and SD of triplicate experiments. One representative from six independent experiments is shown. T cells primed in the presence of anti-CTLA-4 antibody are cytotoxic against specific targets at the 10:1 and 30:1 E/T ratio (Po0.01).
Figure 7
Early but not late CTLA-4 inhibition during sPSMADCs priming enhances T-cell stimulation to subdominant epitopes. HLA A2 (+) PBMCs depleted of monocytes were primed in the presence of blocking anti-CD152 Fab fragments with autologous DCs that had been transfected with sPSMA plasmid. The Fab fragments (0.02 mg/ ml) were added either at the beginning (diamonds), or 6 (squares), 10 (triangles) or 18 (circles) hours after the initiation of culture. Lymphocytes were then cultured for 3 days, then washed, resuspended in IL-2 and IL-7 AIM-V medium and boosted twice at 1-week intervals with autologous PSMA 707 -pulsed monocytes. Cytotoxicity was tested against T2 cells pulsed with the same peptide. Each point represents the mean and SD of triplicate experiments. Representative data from three independent experiments with cells from one donor are shown.
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Antitumor reactivity of PSMA-specific CTLs
The ability of the PSMA-reactive T-cell clones to recognize tumor cells that express PSMA was tested in an in vitro cytotoxicity assay. In all five donors, only two of the peptide-specific CTL lines (PSMA 663 and PSMA 711 ) were cytotoxic against nonmodified LNCaP cells (Fig 8) .
Discussion
Despite being effective in breaking tolerance to a selfantigen or tumor-associated antigen, antitumor vaccination in its current mode of application leads to a narrow response, directed to few of the potential epitopes. Immunodominance is a natural control mechanism that Prime ensures the tight specificity of the immune reaction and prevents untoward autoimmunity. 19 Immunodominance, however, presents a problem in vaccinology since loss of an MHC haplotype that participates in the conformation of the T-cell antigen, or point mutation in the recognized sequence, would result in ineffective immune surveillance. 16, 17 We have explored possibilities to extend the target epitope specificity of the immune response and this study was designed to test the ability of DCs transfected with different plasmid constructs to prime and boost cytotoxic T-cell responses.
A critical requirement for T cell activation is the engagement of TCRs with MHC molecules presenting antigenic peptides on the surface of an APC. 31 Efficient priming of multispecific CTL responses is limited by the poor immunogenicity of subdominant MHC class Ibinding epitopes. 19 T cells binding with high affinity to the antigen compete with low-affinity T cells and inhibit their interaction with the same APC by downmodulation of peptide-MHC complexes on the APC. 32 Inhibition of responses to subdominant epitopes, therefore, could be partially overcome by simply increasing the amount of antigen present on the APCs. [33] [34] [35] We reasoned that, since proteasomal degradation is the main source of antigenic fragments destined for MHC class I presentation, 14 purposeful cytosolic retention of newly synthesized tumor-associated antigens in genetically manipulated APCs may enhance their proteasomal degradation and thus increase the quantity of such fragments. The transport from the cytosol into the endoplasmic reticulum (ER) is an important step in the biogenesis of many proteins, including secretory proteins and proteins of the plasma membrane. It is triggered by a signal sequence, which is normally located at the amino terminus of those polypeptides. For many membrane proteins, the signal sequence is identical with the first membrane anchor (signal-anchor sequence). 36 Since PSMA is a type II, bitopic integral membrane protein, we speculated that elimination of the sequence that encodes for its transmembrane domain will lead to the expression of a product that will not be translocated to the ER, but will be degraded by the proteasomes, presumably into peptides that will access the class I presentation pathway. Indeed, the product expressed following transfection of COS-1 cells with such ''truncated'' construct is not glycosylated, but is retained in the cytosol and rapidly degraded by the proteasomes. This leads to generation of PSMA peptides that are expressed via the class I MHC presentation pathway at density sufficient to prime CTLs to all four PSMA epitopes tested.
On the other hand, DCs transfected with DNA encoding for a product that is translocated to the ER, then glycosylated and secreted, do not prime against subdominant epitopes (Fig 5) . Although all four PSMA epitopes are generated, T cells reactive to the subdominant ones could only be primed if CTLA-4 signaling is inhibited (Fig 6) . Since high-affinity receptor T cells downmodulate peptide-MHC complexes from the APC membrane, 37 increased production of peptides after tPSMA transfection favors subdominant CTL priming.
Stimulation of subdominant MHC-peptide complexes that are expressed at a lower density on the APC membrane following sPSMA transfection, however, requires CTLA-4 inhibition. A homologue of CD28, CTLA-4, also binds to the B-7 family members 38,39 but inhibits T-cell activation. 40 Mice lacking CTLA-4 reveal a striking phenotype of polyclonal T-cell activation and tissue infiltration, which results in death by 3-4 weeks of age, indicating a powerful regulatory role for CTLA-4. 41, 42 Our finding that priming to subdominant responses is enhanced by CTLA-4 inhibition may seem contradictory to the model proposed by others. 43 In that model, CTLA-4 signaling and not inhibition allows for a greater diversity in the T-cell response. Our results, however, support the idea originally proposed by Manzotti et al. 30 It proposes several operational mechanisms, but their clarification requires additional experimentation:
First, the intensity of TCR stimulation seems to be important with weak signals being easily inhibited. 30 In other words, weak signals being overwhelmed by inhibition through CTLA-4 will have no chance to prime CTL responses.
Second, CTLA-4 may act as a nonsignaling ''decoy'' receptor reducing the available ligand for CD28 costimulation. 44, 45 There is also a third possibility. 46, 47 A small number of CTLA4+ T cells may exert a suppressive or regulatory effect on other T cells after stimulation through the CTLA-4 receptor. Such cells appear to be similar if not identical to the T regulatory cells. [48] [49] [50] Experiments are currently in progress to validate any of these hypotheses.
Priming with tPSMA DCs leads to polyclonal CTL stimulation, but boosting with APCs that express both dominant and subdominant epitopes narrows the immune response to the dominant ones. Research from other groups has gained similar results. [51] [52] [53] [54] [55] In all these instances, boosting with polyepitope constructs has resulted in failure to expand polyepitope CTLs. A likely explanation is that competition between T cells for antigen on individual APC leads to obscuring of responses to subdominant epitopes when both the dominant and subdominant epitopes are present on the same APC. 55, 56 New vaccines or new strategies employing modulation of costimulatory networks during boosting may need to be developed if the polyepitope response against a target is to be maintained.
Finally, not all PSMA-peptide-specific CTL clones exhibited tumor cell killing (Fig 8) . A likely explanation for the lack of cytotoxicity is the downregulation of MHC. Unlike other tumor cells, LNCaP cells express low levels of MHC class I molecules. 57 However, neither the level of class I MHC expression, nor the percentage of killing, was influenced by pretreatment of the target cells with g-IFN (data not shown). Alternatively, these subdominant epitopes may not be generated at sufficient quantity by LNCaP cells and further experimentation is necessary to test this possibility.
In conclusion, we have shown that:
(1) DCs transfected with plasmid DNA can successfully prime CTL responses in vitro. (2) DCs transfected with a construct whose product is retained in the cytosol and degraded in the proteasome (tPSMA) prime to both dominant and subdominant epitopes. In contrast, sPSMA DCs prime to dominant epitopes only. (3) CTLA-4 inhibition during priming in vitro enhances priming to subdominant epitopes generated following transfection of DCs with sPSMA. (4) In vitro boosting with APCs that express both dominant and subdominant epitopes narrows the immune response to the dominant ones. If confirmed in animal studies, these results will pose important questions on the design of vaccines and methods for reimmunization if a polyepitope response is to be maintained.
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